Pathophysiological Insights of KIM-1 in Sepsis-Associated Acute Kidney Injury: Insights into the molecular mechanism: A Narrative Review
Abstract
Background
Sepsis-associated acute kidney injury (S-AKI) represents a major clinical challenge, characterized by high incidence, poor prognosis, and limited diagnostic precision with traditional markers such as serum creatinine and urine output. Kidney Injury Molecule-1 (KIM-1), encoded by HAVCR1 on chromosome 5q33.3, has emerged as a sensitive and mechanistically relevant biomarker of tubular injury. This review synthesizes current insights into the.
Methods
A detailed pathophysiology and analysis of transcriptional, epigenetic, and post-transcriptional regulation of KIM-1 in sepsis were conducted using published data. Emphasis was placed on the functions of miRNA (miR21, miR146a and MIR30 family) along with HIF-1α and post-expression functions of KIM-1.
Results
This review highlights Kidney Injury Molecule-1 (KIM-1) as a mechanistically relevant and clinically promising biomarker in sepsis-associated acute kidney injury (S-AKI). Transcriptional activation of HAVCR1 occurs rapidly following endotoxin exposure through TLR4-mediated NF-κB and MAPK signaling, while hypoxia-inducible factor-1α (HIF-1α) synergistically enhances promoter activity under septic hypoxia. miR-21 amplifies pro-inflammatory cascades by silencing PTEN and PDCD4; miR-146a normally restrains NF-κB but is downregulated in sepsis, and the miR-30 family suppresses HAVCR1 translation under physiological conditions but is diminished during sepsis, leading to unchecked KIM-1 overexpression.
Conclusions
KIM-1 bridges molecular injury and clinical outcomes in sepsis-associated AKI, serving both as an effector of tubular stress and as an early biomarker offering diagnostic and prognostic value. While transient expression is protective, persistent activation drives fibrosis and maladaptive repair, underscoring its dual role. Clinical integration of KIM-1 with future research is needed to validate its utility across large cohorts and in combination with other biomarkers.